Exploratory status is stated transparently
The Methods explicitly label the day 0–69 comparisons as ad hoc, disclose the lack of multiplicity adjustment, and state that P values are exploratory.
↳ Methods, Ad Hoc Analyses for Treatment Days 0–69
Abstract
BACKGROUND: Lanadelumab demonstrated efficacy in preventing hereditary angioedema (HAE) attacks in the phase 3 HELP Study.
OBJECTIVE: To assess time to onset of effect and long-term efficacy of lanadelumab, based on exploratory findings from the HELP Study.
METHODS: Eligible patients with HAE type I/II received lanadelumab 150 mg every 4 weeks (q4wks), 300 mg q4wks, 300 mg q2wks, or placebo. Ad hoc analyses evaluated day 0-69 findings using a Poisson regression model accounting for overdispersion. Least-squares mean monthly HAE attack rate for lanadelumab was compared with placebo. Intrapatient comparisons for days 0-69 versus steady state (days 70-182) used a paired t test for continuous endpoints or Kappa statistics for categorical endpoints.
RESULTS: One hundred twenty-five patients were randomized and treated. During days 0-69, mean monthly attack rate was significantly lower with lanadelumab (0.41-0.76) vs placebo (2.04), including attacks requiring acute treatment (0.33-0.61 vs 1.66) and moderate/severe attacks (0.31-0.48 vs 1.33, all P ≤ .001). More patients receiving lanadelumab vs placebo were attack free (37.9%-48.1% vs 7.3%) and responders (85.7%-100% vs 26.8%). During steady state, the efficacy of lanadelumab vs placebo was similar or improved vs days 0-69. Intrapatient differences were significant with lanadelumab 300 mg q4wks for select outcomes. Lanadelumab efficacy was durable-HAE attack rate was consistently lower vs placebo, from the first 2 weeks of treatment through study end. Treatment emergent adverse events were comparable during days 0-69 and 70-182.
CONCLUSION: Protection with lanadelumab started from the first dose and continued throughout the entire study period.
Key Claims
Primary findingSupported
The lower rate of HAE attacks in lanadelumab-treated patients was evident starting from the first 2 weeks of treatment and continued throughout the study.
Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
randomized comparisons support the direction, though short-interval estimates and unadjusted exploratory testing limit certainty
Results, Rapid Onset of Action; Figure 2
SecondarySupported
During days 0-69, mean monthly attack rate was significantly lower with lanadelumab (0.41-0.76) vs placebo (2.04), including attacks requiring acute treatment (0.33-0.61 vs 1.66) and moderate/severe attacks (0.31-0.48 vs 1.33, all P ≤ .001).
the randomized early-period analysis supports lower rates, but multiple unadjusted exploratory comparisons limit confirmatory interpretation
Abstract, Results
SecondarySupported
No treatment-related serious TEAEs nor deaths due to TEAEs occurred during either treatment period.
systematic adverse-event reporting directly supports the statement within the modest trial sample
Results, Safety; Tables 2–3
Derived from the full evaluation — not a separate score.
Strengths · Limitations
Strengths
Early effect has direct clinical relevance
The paper links onset and durability information to clinician and patient decisions about initiating, continuing, and adhering to long-term prophylaxis.
↳ Discussion, clinical-relevance paragraphs
Safety outcomes receive systematic reporting
Treatment-emergent events, serious events, discontinuations, and common adverse events are reported for both analysis periods rather than being omitted from the secondary analysis.
↳ Results, Safety; Tables 2–3
Limitations
Contribution remains an incremental reanalysis
The underlying efficacy evidence was previously reported from the HELP trial; this paper adds temporal characterization through exploratory analyses rather than new independent evidence.
↳ Introduction, final paragraph; Methods, Ad Hoc Analyses for Treatment Days 0–69
Steady-state exclusions lack sensitivity analysis
The day 70–182 analysis omits four placebo participants and one active-treatment participant who discontinued before day 70, without examining how this differential pattern affects the comparison.
↳ Results, opening paragraph
First-dose wording exceeds temporal resolution
The Conclusion says protection started from the first dose, while the directly reported interval demonstrates a lower attack rate within the first two weeks.
↳ Abstract, Conclusion; Results, Rapid Onset of Action; Figure 2
Nabu Commentary
The randomized, double-blind parent trial and complete day 0–69 analysis support the direction of the early attack-rate findings. The Methods appropriately identify the analyses as ad hoc, disclose unadjusted multiplicity, and restrict the early-period analysis from serving as a basis for dose selection. The principal methodological deduction reflects the exclusion of four placebo participants and one active participant from the steady-state analysis without sensitivity testing. Clinical relevance is clear for expectation-setting and adherence, but the contribution and transferability remain bounded by reuse of one selected phase 3 cohort.
Check another paper
Author Note / Field Feedback
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Dimension breakdown
Study Quality
Sound3.4
Confidence highContribution
3.2
The paper adds clinically useful detail about onset and durability but does not provide a new trial or establish the underlying efficacy result anew. Its contribution is therefore genuine but incremental.
Introduction, final paragraph; Methods, Ad Hoc Analyses for Treatment Days 0–69
“Herein, we report exploratory findings from ad hoc analyses from the HELP Study.”
Methodological Rigour
3.4
The blinded parent trial, Poisson rate model, complete day 0–69 analysis, and systematic harms reporting provide a competent foundation. The day 70–182 analysis excludes four placebo and one active participant without a sensitivity analysis, reducing certainty in the steady-state comparison.
Methods, Study Design and Ad Hoc Analyses; Results, opening paragraph; Tables 2–3
“Patients who discontinued prior to day 70…were not included.”
Reporting
3.8
The paper clearly separates the original endpoints from the ad hoc analyses and repeatedly identifies exploratory, unadjusted testing. The phrase “started from the first dose” is less precise than the reported evidence of benefit within the first two weeks.
Abstract, Methods, Ad Hoc Analyses; Results, Figure 2; Conclusion
“Protection with lanadelumab started from the first dose.”
Positioning
3.5
The Discussion relates the findings to the parent HELP trial, a COMPACT post hoc analysis, and prophylaxis decisions, while warning against dose selection from the early window. Broader comparative evidence and systematic treatment of limitations remain limited.
Discussion, paragraphs 2–4 and final clinical-relevance paragraphs
“Caution is required when interpreting data over short time periods.”
Lower confidence on Methodological Rigour, Positioning — domain match limited.
Reliability
Caveats4 of 4 checks
Internal CoherenceNoted
The numerical reporting is internally consistent and the analyses are repeatedly identified as exploratory. Minor concerns remain around the precision of the first-dose wording and the unanalysed differential exclusions from the steady-state comparison.
Research ConductNoted
Ethics, consent, trial registration, and conflicts are disclosed. Extensive sponsor involvement and financial interests are a transparent contextual watch-out rather than evidence of concealed misconduct.
Flags: 3 declared / 5 total
Reference IntegrityClean
21 of 21 checkable references verified
27 references in manuscript 6 are books, websites or datasets — counted, but not index-checkable
Post-Publication RecordClean
No retraction notice found in Retraction Watch.
Last checked: 18 Sep 2026
Sources: Retraction Watch ✓
Readiness
Where this paper’s evidence sits on the path from initial observation to real-world use.
Validated
Lanadelumab is already approved, so the analysis supplies clinically interpretable characterization of an operational therapy. Its exploratory design and lack of implementation guidance limit immediate actionability of the specific onset claim.
Introduction, lanadelumab approval paragraph; Discussion, clinical-relevance paragraphs
AI-generated, human-governed. Something look off? Contact us to request a review.